Categories

Above the Fold

#HealthTechDeals Episode 6: Alto Pharmacy, Althelas, A Place for Mom, And Summus Global

In Episode 6 of Health Tech Deals, Jess and I might be two new characters and Sesame Street! Keep watching to find out which ones. Some new deals, brought to you by the letter A: Alto Pharmacy raises $200 million; Athelas raises $132 million; A Place for Mom raises $175 million; and Summus Global raises $22 million. -Matthew Holt

Jessica DaMassa:              Well, hello, Matthew Holt. I have an important question for you. It looks like all of the deals we have to talk about today start with the letter ‘a’, which leads me to believe that we might be two new characters on Sesame Street. Now, are we more like Ernie and Bert or Oscar the Grouch and Big Bird? Those are the important questions that we’re asking here on the February 2nd episode of “Health Tech Deals”.

Matthew Holt:                   So Jessica. I’m very tall, so I must be Big Bird, and you must be Oscar the Grouch.

Jessica DaMassa:              Don’t think so.

Matthew Holt:                   All right? Maybe the other way. Anyway, it’s all brought to you by the letter ‘a’.

Continue reading…

New Cancer Care Navigator Thyme Care Starts Out with $22M Series A & Big Name Backing

By JESSICA DaMASSA, WTF HEALTH

Thyme Care is a cancer navigation platform that is looking to use technology to make the kind of high-touch care coordination usually only found at Centers of Excellence available to oncology practices across the country. The navigation we’re talking about is typically quarterbacked by experienced oncology nurse navigators, and is known to have a direct impact on a patient’s experience and their health outcomes. Thyme Care’s platform not only scale-ups this expertise, but also augments it with analysis of claims data and EMR data to help those navigators quickly detect which patients might be at higher risk for poor outcomes and which interventions might help mitigate those risks – whether that be addressing social determinants of health issues like transportation to appointments, or just more quickly spotting gaps in care.

Thyme Care’s President & Chief Medical Officer Bobby Green (an oncologist himself) introduces us to the tech platform and explains how, among a competitive field of tech-enabled care navigators, it’s managed to stand apart enough to win Medicare Advantage plan Clover Health as an early client and to gain a $22 million dollar Series A investment from platform-savvy investors like Andreessen Horowitz and AlleyCorp. (Frist Cressey Ventures, Casdin Capital and Bessemer also participated in the round, which was announced in October 2021.)

As the business looks to scale, what’s to make of all its connections to Flatiron Health, arguably health tech’s best-known cancer care platform? Lots of alumni on the cap table and in the biz, including Bobby himself! Find out more about expansion plans and points of differentiation in this quick get-to-know-you chat.

Spotify, Joe Rogan, and Health Care

By KIM BELLARD

Here’s a sentence I never thought I’d have to write: the most interesting discussion in healthcare in the past week has been about Neil Young versus Spotify.  

For those of you who have not been following the controversy, Neil Young gave Spotify an ultimatum: it could have his music or Joe Rogan, but not both.  “I am doing this because Spotify is spreading fake information about vaccines – potentially causing death to those who believe the disinformation being spread by them.”  Spotify chose Rogan.

Mr. Young was not the first to express alarm at some of the Covid “information” promoted on Mr. Rogan’s podcast, The Joe Rogan Experience (JRE); in December, for example, several hundred scientists from around the world issued an open letter to Spotify specifically about JRE, warning:

By allowing the propagation of false and societally harmful assertions, Spotify is enabling its hosted media to damage public trust in scientific research and sow doubt in the credibility of data-driven guidance offered by medical professionals.

Continue reading…

Matthew’s health care tidbits: #What is insurance again?

Each week I’ve been adding a brief tidbits section to the THCB Reader, our weekly newsletter that summarizes the best of THCB that week (Sign up here!). Then I had the brainwave to add them to the blog. They’re short and usually not too sweet! –Matthew Holt

For my health care tidbits this week, I was reminded on Twitter that many Americans really don’t understand health insurance. A spine surgeon no less in this thread (no jokes about arrogance please) was telling me that he was paying ~$8,000 a year ($4,000 in insurance and $4,000 in deductible) before he got to “use” his insurance–which, as his medical costs were low, he never did. Others were complaining that the cost of employee premiums were over $20K. They all said they should keep the money and (presumably) pay cash when they do use the system. It’s true that most people don’t use their insurance. That’s the whole point. When you buy house insurance, you don’t expect your house to burn down. You are paying into a pool for the people whose house does burn down.

In the US we are on average spending $12k per person on health care each year. But spending on most people is way under that and for a few it’s way, way over. If you take the rough rule that 50% of the spending is on 10% of the people then 35 million people account for $2 trillion in spending–that’s ballpark $60,000 each. They are the ones with cancer, heart disease, complex trauma, etc, etc. The rest of us are “paying” our $4,000, $8,000 whatever, into the pool to cover that $60,000.

There are only two ways to lower that cost for the healthy who aren’t “using” their insurance. One is to exclude unhealthy people from that insurance pool, which makes the costs for everyone else much less. We did that for years with medical underwriting and it was nuts because it screws over the unhealthy. Fixing the pre-existing condition exclusions was the only bit of Obamacare everyone agrees on–even Trump. But now we are ten plus years into this new reality, some people have forgotten how bad it was before.

The other way is to reduce the costs in the system and lower that $4 trillion overall. How to do that is a much longer question. But it isn’t much connected to the concept of insurance.

The Social Science of Covid

By MIKE MAGEE

As we enter the third year of the Covid pandemic, with perhaps a partial end in sight, the weight of the debate shows signs of shifting away from genetically engineered therapies, and toward a social science search for historic context.

Renowned historian, Charles E. Rosenberg, envisioned a similar transition for the AIDS epidemic in 1989. He described its likely future course then as a “social phenomenon” with these words, “Epidemics start at a moment in time, proceed on a stage limited in space and duration, follow a plot line of increasing and revelatory tension, move to a crisis of individual and collective character, then drift toward closure.”

Continue reading…

Inside Wheel’s $150M Series C: CEO Talks “Long Game” for Stealthy Virtual Care Infrastructure Biz

By JESSICA DaMASSA, WTF HEALTH

Wheel’s CEO Michelle Davey says the white-label virtual care startup’s $150M Series C – led by notable health tech mega-funders Lightspeed Venture Partners & Tiger Global – is “really about the long-game.” We get into the details of this purposeful funding round and what it means for the future of Wheel, as well as the play-by-play analysis of what happened over the past 9 months, since the company closed its $50M Series B. (FYI: Wheel’s total funding is at $216 million to-date.)

Wheel is currently running behind-the-scenes for an undisclosed client list of brands, facilitating 1.6 million virtual visits a year for digital health companies, digital pharmacies, retailers, and, now, even traditional healthcare providers. That number is expected to triple by the end of 2022, and we get into what’s fueling that growth and whether or not Michelle believes that this institutional push toward online care will persist as the pandemic wans and the world continues re-opening.

Armed with this fresh funding, how will three-year-old Wheel continue to differentiate its offering from legacy telehealth infrastructure providers like Amwell and Teladoc? How will it win against their legacy relationships with legacy healthcare providers? Or, is Wheel’s big bet on the continued scaling of what Michelle calls “next generation healthcare”? Wheel has added A LOT of tech to its own infrastructure recently, providing asynchronous options, better clinician matching, more triaging and navigating, and, with this funding, are is now talking about adding “diagnostic services” to round out their service line. What, exactly are we talking about here in terms of business model evolution? Tune in and find out what this stealthy startup is up to!

THCB Gang Episode 80, Thursday Jan 27

Joining Matthew Holt (@boltyboy) on #THCBGang for an hour of conversation on the happenings in health care and beyond were regulars medical historian Mike Magee  (@drmikemagee) and writer Kim Bellard (@kimbbellard), and TWO special guests.

Shantanu Nundy @DrNundy  is Chief Medical Officer of Accolade and last year we had him on to talk about his book Care After Covid. This week, with Lisa Cooper and Kedar Mate he wrote in Jama adding “advancing health equity” as a new part of the “quintuple aim.”

Our second guest was Janae Sharp @CoherenceMed from the Sharp Index, which is dedicated to increasing awareness of and reducing physician suicide and burnout through support and data science

Were we ever going to be able to cover everything about physician burnout and health equity in just one hour? Yes, it was unlikely but we gave it our best shot!

The video is preserved below. If you’d rather listen to the episode, the audio is available from Friday as a weekly podcast available on our  iTunes & Spotify channels. 

Big Health’s Softbank Money, FDA Board Member Send Strong Signals About Digital Therapeutics Market

By JESSICA DaMASSA, WTF HEALTH

With a $75 million investment from Softbank last week, and the addition of former FDA Deputy Commissioner Dr. Anand Shah to its Board of Directors this week, Big Health has sure kicked 2022 off with some noise! But, this is more than just big news for Big Health as CEO Peter Hames is here to tell us. This is a story about the market potential for an all-tech approach to mental health care, AND an important endorsement for digital therapeutics – specifically, those that do NOT require a prescription.

Big Health sits at the intersection of two of the hottest health-tech markets: digital mental health care and digital therapeutics. Its approach, via apps Daylight (for anxiety) and Sleepio (for insomnia), has been flagged as unique because 1) unlike other leading digital mental health companies like Headspace Health or Lyra Health, Big Health’s approach to care is tech-driven and does not depend on coach or clinician intervention, and 2) unlike its digital therapeutics rivals, Pear Therapeutics or Click Therapeutics, Big Health’s business model isn’t relying on prescriptions to get paid.

Big Health is, in other words, proving the market potential for a different “breed” of tech-first, PBM-backed digital therapeutics, and I ask Peter about it head-on as we discuss Softbank’s investment. The mega-fund has placed bets on all sides now, having invested in Cerebral, which delivers clinician-first mental health care and prescription medication, and prescription DTx company Pear, which went public in December 2021. So, what should the market make of the fact that Softbank sees room for Big Health alongside Cerebral and Pear? How have high-profile deals with CVS Health and the NHS in Scotland proven out the model? And, what does the addition of Anand Shah (and his insider perspective on the FDA’s sentiment toward digital therapeutics) indicate about what’s ahead when it comes to the regulatory environment for DTx in the future? So many market dynamics at play, so much to talk about!

#HealthTechDeals Episode 5: Infermedica, Wellster, Casana, Babylon, and Atlas Health

How many more beloved TV characters does Peleton have to give a heart attack to before somebody steps in? Jess can’t take it anymore, and we hash out some new deals: Infermedica raises $30 million; Wellster gets a fresh $20 million; Casana the smart toilet seat maker raises $30 million; Babylon buys DaytoDay Health and Higi; Atlas Health raises $40 million. -Matthew Holt

TRANSCRIPT

Jess DaMassa:

Matthew Holt, how are we not talking about one of the single greatest health tech health crises of our time?

Matthew Holt:

What could that possibly be?

Jess DaMassa:

How many more beloved TV characters does Peloton have to give a heart attack too before somebody steps in? I can’t take anymore.

Matthew Holt:

I think the SEC is about step in. Is that for the heart attacks or is that for all the stock sales by the CEO?

Jess DaMassa:

Causing a real heart attack but for a whole different group of people. It’s January 26th episode of Health Tech Deals.

Continue reading…

Infermedica raises a big round and demos new product

Infermedica is a company that started by creating symptom checking and chatbot functionality in Poland back in 2012. It’s spread to delivering that patient-facing diagnosis functionality via API and now as preparation for a physician visit. Today they announce a $30m series B and demo their new product which helps prepare a visit, and integrates into the clinician workflow. I spoke with CEO Piotr Orzechowski and Chief Product Officer Tim Price–Matthew Holt.

assetto corsa mods